Guggenheim Capital LLC Has $14.33 Million Holdings in Eli Lilly And Co (NYSE:LLY)
Guggenheim Capital LLC lessened its stake in Eli Lilly And Co (NYSE:LLY) by 44.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 103,317 shares of the company’s stock after selling 82,154 shares during the quarter. Guggenheim Capital LLC’s holdings in Eli Lilly And Co were worth $14,332,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Eli Lilly And Co during the fourth quarter worth $1,171,509,000. Jennison Associates LLC lifted its stake in Eli Lilly And Co by 125.9% in the first quarter. Jennison Associates LLC now owns 10,192,052 shares of the company’s stock valued at $1,413,841,000 after acquiring an additional 5,679,574 shares during the last quarter. BlackRock Inc. raised its position in shares of Eli Lilly And Co by 5.6% in the first quarter. BlackRock Inc. now owns 64,299,477 shares of the company’s stock valued at $8,919,623,000 after purchasing an additional 3,420,265 shares during the period. APG Asset Management N.V. raised its position in shares of Eli Lilly And Co by 668.1% in the first quarter. APG Asset Management N.V. now owns 2,660,838 shares of the company’s stock valued at $307,495,000 after purchasing an additional 2,314,410 shares during the period. Finally, Capital World Investors raised its position in shares of Eli Lilly And Co by 128.4% in the first quarter. Capital World Investors now owns 3,034,849 shares of the company’s stock valued at $420,994,000 after purchasing an additional 1,706,354 shares during the period. Institutional investors own 77.44% of the company’s stock.
In other Eli Lilly And Co news, SVP Aarti S. Shah sold 2,000 shares of the stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $150.00, for a total transaction of $300,000.00. Following the sale, the senior vice president now directly owns 19,087 shares in the company, valued at $2,863,050. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 53,770 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $161.54, for a total transaction of $8,686,005.80. Following the completion of the sale, the insider now owns 111,798,270 shares in the company, valued at $18,059,892,535.80. The disclosure for this sale can be found here. Insiders have sold 1,164,427 shares of company stock worth $175,530,418 over the last quarter. Corporate insiders own 0.09% of the company’s stock.
Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 23rd. The company reported $1.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.48 by $0.27. The firm had revenue of $5.86 billion for the quarter, compared to the consensus estimate of $5.48 billion. Eli Lilly And Co had a net margin of 23.97% and a return on equity of 194.18%. The business’s revenue for the quarter was up 15.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.33 earnings per share. On average, analysts expect that Eli Lilly And Co will post 6.82 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were paid a dividend of $0.74 per share. The ex-dividend date of this dividend was Thursday, May 14th. This represents a $2.96 dividend on an annualized basis and a yield of 1.84%. Eli Lilly And Co’s payout ratio is 49.01%.
LLY has been the topic of several research analyst reports. Mizuho increased their price objective on shares of Eli Lilly And Co from $148.00 to $155.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Goldman Sachs Group raised shares of Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 price objective on the stock in a research report on Wednesday, March 11th. UBS Group lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and increased their price objective for the company from $157.00 to $158.00 in a research report on Monday, April 20th. Bank of America reissued a “buy” rating and issued a $180.00 price objective on shares of Eli Lilly And Co in a research report on Friday, June 19th. Finally, Cfra raised their price target on shares of Eli Lilly And Co from $146.00 to $167.00 and gave the stock a “hold” rating in a research report on Friday, April 24th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $167.83.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: Federal Reserve
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.